Generated September 21, 2026 at 8:32 PM ET
· Covers September 21 trading day
· 10 of 169 ready 8-Ks selected
· AI-assisted overview
Today's 8-K filings highlighted several significant developments. Sangamo Therapeutics sold its Fabry gene therapy ST-920 to PTC for $111M in cash, while Priority Technology Holdings agreed to be taken private at $8.05 per share in an all-cash deal valued at roughly $1.6B. Algorhythm Holdings acquired Azure Energy's renewable assets for $23M in stock and named a new CEO, and Electra Therapeutics closed a $350M IPO at $15.00 per share. On the regulatory and clinical front, NewAmsterdam Pharma received European Commission approval for obicetrapib, and Cue Biopharma reported positive Phase 2 data for CUE-221. Additionally, Optimum Communications announced it will restate prior financials due to deferred tax errors.
PLAY
Dave & Buster's Entertainment, Inc.
leadership
positive
materiality 0.70
September 21, 2026, 2:16 PM ET
Dave & Buster's appoints new COO and CAO; multiple C-suite promotions
- Amanda Busby named COO; $450k salary, 70% bonus target, 72,464 RSUs, 74,294 options at $8.97, PSUs.
- Derek Sample named CAO; $315k salary, 50% bonus target, 39,019 RSUs, 52,006 options at $8.97, PSUs.
- Promotions: Rachel Morgan (Chief Legal & Admin Officer/Secretary), Aldo Rosales (Chief Strategy & Rev Mgmt), Jeremy Tucker (CMO), Kevin Fish (CTO).
SGMO
SANGAMO THERAPEUTICS, INC
M&A
negative
materiality 0.90
September 21, 2026, 4:01 PM ET
Sangamo sells Fabry gene therapy ST-920 to PTC for $111M cash; Nasdaq delisting Sept 27
- Completed Sept 17, 2026 sale of ST-920 (isaralgagene civaparvovec) to PTC Therapeutics for $111M cash at close.
- Up to $100M in additional milestone-based contingent consideration; PTC assumes specified liabilities.
- Court approved sale Sept 2, 2026 (Docket No. 426) following Aug 10 auction where PTC was successful bidder.
PRTH
Priority Technology Holdings, Inc.
M&A
positive
materiality 1.00
September 21, 2026, 7:40 AM ET
Priority Tech to be taken private at $8.05/share cash by CEO-led group; EV ~$1.6B
- Merger agreement with WD Capital Partners (controlled by CEO Thomas Priore) values PRTH at $8.05/share cash, 65% premium to Nov 7, 2025 close and 38% premium to Sept 18, 2026 close.
- All-cash deal has enterprise value of approximately $1.6 billion; special committee unanimously recommended and board approved with Priore and Crisafulli recusing.
- Supporting stockholders owning ~61.4% of shares committed to vote for deal and roll over equity; financing includes up to $160M from Searchlight Capital.
RIME
Algorhythm Holdings, Inc.
M&A
positive
materiality 0.90
September 21, 2026, 5:17 PM ET
Algorhythm acquires Azure Energy renewable assets for $23M stock; new CEO appointed
- Acquired substantially all assets of Azure Energy for $23M in Parent stock: 4,076,312 common shares (19.99%) and 22,038 Series B preferred.
- Option to buy 79.0286% of Azure Energy S.R.L. for $30M exercise price, exercisable for 36 months; up to 50% cash, balance in Series B preferred.
- CEO Gary Atkinson and CFO Alex Andre terminated; Andrew Thompson named CEO, Ryan Smith COO, Leticia Raele interim CFO and CAO.
NAMS
NewAmsterdam Pharma Co N.V.
regulatory
positive
materiality 0.85
September 21, 2026, 4:30 PM ET
European Commission approves obicetrapib (Ubeslo/Evlarco) for hypercholesterolaemia; first approval worldwide
- EC granted marketing authorization for Ubeslo (obicetrapib 10mg) and Evlarco (obicetrapib+ezetimibe FDC) for primary hypercholesterolaemia or mixed dyslipidaemia; first global approval.
- Authorizations cover all EU states plus Iceland, Liechtenstein, Norway; require post-authorization efficacy study, including final PREVAIL outcomes trial results.
- Menarini holds exclusive EU commercialization rights; NewAmsterdam receives tiered double-digit royalties (low double-digits to mid-twenties %) on net sales.
debt
positive
materiality 0.80
September 21, 2026, 4:09 PM ET
OppFi borrows $75M term loan; BNCC stockholders approve acquisition
- Borrowed $75M on Sep 15, 2026 under up-to-$100M multi-draw term loan at 12.50% (13.50% post-acquisition), 1.25% OID, 4-yr maturity.
- $25M undrawn available until Feb 10, 2027; semi-annual amortization 10% of funded principal; no reborrowings after repayment.
- Proceeds to support growth in finance receivables and working capital; guaranty and lien on assets of OppFi-LLC and SPVs.
LHAI
Linkhome Holdings Inc.
regulatory
positive
materiality 0.50
September 21, 2026, 4:30 PM ET
Linkhome regains Nasdaq minimum bid price compliance; delisting matter closed
- On June 29, 2026, Nasdaq notified LHAI that bid price was below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).
- On Sept 18, 2026, Nasdaq confirmed closing bid price was at least $1.00 for 10 straight business days (Sept 3–17, 2026).
- Nasdaq determined LHAI regained compliance with the Minimum Bid Price Requirement; the matter is now closed.
ETRA
Electra Therapeutics, Inc.
other material
positive
materiality 0.90
September 21, 2026, 4:01 PM ET
Electra Therapeutics closes $350M IPO at $15.00/share
- Closed IPO of 23,333,334 shares at $15.00/share; gross proceeds ~$350.0M.
- IPO closed Sept 21, 2026; shares trade on Nasdaq Global Select Market under ETRA.
- Amended and restated certificate of incorporation and bylaws effective upon IPO closing.
OPTU
Optimum Communications, Inc.
other material
negative
materiality 0.85
September 21, 2026, 5:00 PM ET
Optimum Communications restating FY2025 and interim 2026 results on deferred tax errors
- Restating FY2025, Q3 2025, Q1 2026, Q2 2026 financials due to understated deferred tax benefits and overstated deferred tax liability.
- Expected net loss reductions: ~$430M for FY2025 and Q3 2025; ~$720M for Q1 and Q2 2026.
- No impact on cash, revenues, capex, cash flows, EBITDA, or pre-tax loss; only tax-related balance sheet items.
other material
positive
materiality 0.85
September 21, 2026, 8:00 AM ET
Cue Biopharma: CUE-221 Phase 2 in CSU meets primary and key secondary endpoints
- Phase 2 trial (N=145) met primary endpoint HSS7=0 at week 12 at all doses: 54% (4mg/kg) vs 11% placebo, p<0.005.
- Key secondary endpoint UAS7=0 met at 4mg/kg: 46% vs 11% placebo, p<0.05; dose-responsive.
- Safety favorable: no treatment-related SAEs or anaphylaxis; only one >grade1 injection site reaction, none led to discontinuation.